Mycosis fungoides
Therapeutic area
Dermatology
Rare disease
Yes
- Definition
- Classical mycosis fungoides is the most common type of mycosis fungoides (MF), a form of cutaneous T-cell lymphoma, and is characterized by slow progression from patches to more infiltrated plaques and eventually to tumors.
- Genetic basis
- Yes
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Mycosis fungoides
- Therapeutic area
- Dermatology
- mycosis fungoides
- CTCL/ mycosis fungoides
- MF
- cutaneous T-cell lymphoma/mycosis fungoides
- mycosis fungoides
- mycosis fungoides (morphologic abnormality)
- mycosis fungoides NOS (morphologic abnormality)
- mycosis fungoides of unspecified site
- mycosis fungoides, Alibert-Bazin type
- mycosis fungoides, unspecified site, extranodal and solid organ sites
- Alibert-Bazin syndrome
- granuloma fungoides
- Severity
- Severe
- Dermatology
- Hematology
- Oncology
- MONDO ID
- MONDO:0009691
- Parent condition
- MONDO:0000607
Related records
Broader conditions (27)
- Cancer
- Cancer or benign tumor
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
- Human disease
- Indolent primary cutaneous T-cell lymphoma
- Integumentary system cancer
- Integumentary system disorder
- Lymphoid hemopathy
- Lymphoid neoplasm
- Lymphoma
- Mycosis fungoides and variants
- Neoplasm
- Neoplastic disease or syndrome
- Non-Hodgkin lymphoma
- Primary cutaneous lymphoma
Trials (451)
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 17-Dimethylaminoethylamino-17-demethoxygeldanamycin (17-DMAG) in Treating Patients With an Advanced Solid Tumor or Lymphoma
- 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas
- 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma
- 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery
- 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- 506U78 in Treating Patients With Lymphoma
- 506U78 in Treating Patients With Recurrent or Refractory Cutaneous T-cell Lymphoma
- A Clinical Trial of Flonoltinib Maleate for Intermediate or High-Risk Myelofibrosis
- A Clinical Trial of Flonoltinib Maleate Tablets in the Treatment of JAK Inhibitor Refractory/Relapsed/Intolerant Patients With Intermediate to High Risk Myelofibrosis
- A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
- A Phase 1, Multicenter, Open-label, Prospective, First-in-human Dose-escalation Clinical Trial of Domain Therapeutics' Anti-CCR8 Monoclonal Antibody (DT-7012) in Patients With Relapsed or Refractory Cutaneous T-cell Lymphomas (CTCL)
- A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
- A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL
- A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)
- A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
Approved drugs (7)
- Dexamethasone
- Dexamethasone sodium phosphate
- Mechlorethamine
- Methotrexate
- Mogamulizumab
- Prednisolone
- Prednisone
Drugs in development (61)
- 6-O-benzylguanine Phase 1
- Acimtamig Phase 2
- Agatolimod sodium Phase 1
- Aldesleukin Phase 1
- Alemtuzumab Phase 2
- Aminolevulinic acid hydrochloride Early phase 1
- Atezolizumab Phase 2
- Belinostat Phase 1
- Bexarotene Phase 3
- Brentuximab vedotin Phase 3
- Carfilzomib Phase 1
- Carmustine Phase 1
- Cemiplimab Phase 1
- Ciaftalan Phase 1
- Cobomarsen Phase 2
- Copanlisib hydrochloride Phase 1
- Cyanocobalamin Phase 1
- Cyclophosphamide Phase 1
- Cyclosporine Phase 1
- Daratumumab Phase 1